fashion -WSS

fashion

author：knowledge 2025-08-27 16:47:28 - browse：37535

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

WSS

Has Bernie Sanders reached the limit of his pharma bullying effort?

Readout LOUD podcast: live from JPM 2024

New England Journal of Medicine addresses racist history, slavery

Black vets could get higher VA benefits if race not used in lung test

Primary care doctor shortage won't be solved by free med school tuition

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

fashion

hotspot

Continuity nursing helped my family in our darkest PICU moments

The effects of a landmark ruling on DNA ownership are becoming clearer

Bright Health sells Medicare Advantage business to Molina

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Activists slam private health insurers over coverage restrictions

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Activists slam private health insurers over coverage restrictions

New England Journal of Medicine addresses racist history, slavery

hotspot

HHS's proposed rule does nothing to address the climate crisis

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Novel spinal cord stimulator treats paralysis without surgery

Idaho abortion case may prompt more restrictions in other states

The effects of a landmark ruling on DNA ownership are becoming clearer

The nurse manager staffing crisis is hurting patients

entertainment

leisure time

hotspot

explore